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The United States Department of Health and
Human Services (DHHS) first published
Guidelines for the Use of Antiretroviral Agents in
HIV-1-Infected Adults and Adolescents on April
24th, 1998.  Commonly referred to as the DHHS
Guidelines or simply The Guidelines, they rep-
resent the consensus opinion of the Panel on
Clinical Practices for Treatment of HIV. The
Panel, which is referred to many times is this
article, is appointed and convened by the DHHS
and is composed of basic and clinical
researchers as well as clinicians, participants
from the DHHS, and nonvoting observers.  The
panel has monthly conference calls and meets
in person at least twice per year to review pub-
lications and information from scientific meet-
ings and to issue updates as new information
regarding the treatment of HIV emerges.  Not
only do these guidelines provide the most up-to-
date information regarding HIV care, they have
also helped to set an acceptable standard of
care for the treatment of HIV in the United
States, which would also apply to the care of
persons incarcerated in jails and prisons. The
most recent update of the guidelines was pub-
lished on October 29th, 2004 and is available at
http://www.hhs.gov. This article will serve to
summarize those modifications of the guidelines
that are relevant to correctional health care
providers.
WHAT IS NEW IN THIS VERSION OF THE
GUIDELINES
Changes in recommendations in this latest revi-
sion have to do with the initiation of antiretrovi-
ral therapy (ART) in ART-naïve patients. These
include an increase in the viral load recommen-
dation to defer or consider therapy from 55,000
copies/mm3 to 100,000 copies/mm3 in asympto-
matic patients with a CD4 cell count greater
than 350 cells/mm3. Stavudine has been
changed from a "preferred" to an "alternative"
agent; and tenofovir and lamivudine (or emtric-
tabine) are now recommended as preferred or
alternative nucleoside (or nucleotide) back-
bones in protease inhibitor (PI) as well as non-
nucleoside reverse transcriptase inhibitor
(NNRTI)-based regimens.
Additions to The Guidelines include a section on
special populations; a discussion on discontinu-
ation or interruption of ART, and several new
tables showing data about the probability of pro-
gressing to AIDS, data from 48-week treatment
trials, and revised tables on ART associated
adverse events.
Any mention of hydroxyurea has been deleted
from The Guidelines since the Panel feels it
should limit its commentary to FDA-approved
agents with indications for the treatment of HIV
infection. 
These changes and additions will be discussed
in the general context of the primary care of HIV
infected patients outlined in this update.
EXPERTISE IN THE TREATMENT OF HIV
INFECTION
The guidelines continue to emphasize the
importance of HIV expertise in "clinical care"
since multiple studies have shown better out-
comes when HIV-experienced treaters care for
HIV infected patients. The Panel recommends
HIV primary care by a clinician with at least 20,
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but preferably 50 HIV-infected patients and
the guidelines also suggest that these HIV
providers fulfill CME requirements on HIV-
related topics.
PRETREATMENT EVALUATION
The basic pretreatment "intake" evaluation
for HIV care is aimed at confirming HIV
infection and whether it is acute, identifying
co-infections, and assessing the overall
health of the patient. A complete history
and physical examination should be per-
formed. Factors that are known to affect
adherence to therapy, including substance
abuse, economic factors, need for social
support, psychiatric illness, and other co-
morbidities should be identified and if pre-
sent, managed with available resources.
The initial laboratory evaluation should
include HIV antibody testing if confirmation
of infection is not available, CD4 cell count,
plasma HIV RNA, CBC, chemistry profile,
transaminase levels, BUN and creatinine,
urinalysis, serologic testing for syphilis,
tuberculin skin testing, fasting blood glu-
cose, serum lipids levels and serologies to
measure antibodies to Toxoplasma gondii,
Hepatitis A, B, and C.  Women should have
a PAP test. Testing for infection with
Chlamydia trachomatis and Neisseria gon-
orrhea is optional and a chest radiograph
should be performed if clinically indicated. 
CD4 CELL COUNT AND VIRAL LOAD
The CD4 cell count and the plasma HIV
RNA to measure HIV viral load (VL) remain
the two key serologic markers that are rou-
tinely used to determine when to initiate
ART and to monitor ongoing efficacy of
treatment. In general, VL and CD4 should
be monitored every three to four months
with more frequent assessments of the VL
occurring when ART is initiated or
changed.  
The Panel recommends that VL be mea-
sured immediately before instituting or
changing treatment and again two to eight
weeks after treatment initiation or change.
The results of this test help guide treatment
and therefore limitations on VL testing that
may be imposed in correctional settings
(such as once every three months) would
not apply in this situation. The primary goal
of therapy remains a reduction in VL below
the limits of detection and this can be
achieved within 16-24 weeks of initiation of
therapy.  
The Food and Drug Administration has
approved three VL assays, any of which
can be used (most correctional systems will
have selected one for use by all of their
practitioners). Since VL testing can be used
to evaluate control of HIV, "ultrasensitive"
tests (that measure VL down to the lowest
number of copies/mm3) should be used
when changing therapy or evaluating the
effectiveness of therapy. Available VL
assays are summarized in Table 1.
WHEN TO TREAT
Table 2 summarizes Panel recommenda-
tions for initiation of ART. The primary
change in these recommendations is the
increase in VL from 55,000 to 100,000
copies/mm3 as a cutoff for when to consid-
er initiation of therapy. This trend towards
delaying therapy based on VL determina-
tion is supported by data demonstrating
that the risk for progression to AIDS within
six months is greatest in those with a VL
higher than 100,000 copies/mm3 whose
CD4 cell count is less than 200 cells/mm3.
Conversely, in most individuals who have
VL less than 100,000 copies/mm3 and a
CD4 cell count greater than 350 cells/mm3,
the risk of progression to AIDS within six
months is less than 2%.
In patients who are in care and having reg-
ular monitoring of VL, CD4 cell count, and
clinical status, deferring therapy can pro-
vide extra time for addressing issues of
substance use, psychiatric illness, other
co-morbidities and extra time for education
and preparing the patient to accept potent
combination therapy aimed at suppressing
VL to undetectable levels. The guidelines
were changed in the hope that deferring
therapy will decrease the long-term compli-
cations of ART by decreasing total expo-
sure time to ART drugs. The correctional
clinician should schedule regular follow up
visits to monitor the patients' readiness for
therapy. These visits provide an additional
opportunity for education about the risks
and benefits of ART.
INITIAL COMBINATION REGIMENS FOR
THE ANTIRETROVIRAL -NAÏVE
PATIENT
There are currently 20 different drugs
belonging to four different classes that can
be used to create combination regimens
that are potent enough to suppress plasma
viremia to nondetectable levels. These four
classes are nucleoside/ nucleotide reverse
transcriptase inhibitors (NRTI), nonnucleo-
side reverse transcriptase inhibitors
(NNRTI), protease inhibitors (PI) and fusion
inhibitors (FI). The Panel prefers to call
these combinations "potent combination
ART" rather than Highly Active
Antiretroviral Therapy (HAART). Current
ecommendations for treatment combina-
tions are organized based on the three
types of regimens for which there is infor-
mation from clinical trials and clinical expe-
rience. These three combinations are
NNRTI-based (1 NNRTI +2 NRTI), PI-
based (1-2 PI + 2 NRTI), and triple NRTI-
2
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Table 1.  U.S. FDA Approved VL Assays
TEST
HIV 1 reverse transcriptase poly-
merase chain reaction assay
(Amplicor HIV-1 Monitor Test, 
version 1.5
Nucleic acid amplification test for
HIV RNA (NucliSens HIV -1 QT)
Signal amplification nucleic acid
probe assay (VERSANT HIV 1
RNA 3.0 assay)
Manufacturer
Roche Diagnostics
Organon Teknika
Bayer
Lower limit of detection
<50 copies per ml
<80 copies per ml
<75 copies per ml
Table 2.  Recommendations for Initiating ART
Clinical Category
AIDS-defining 
illness or severe
symptoms*
Asymptomatic
Asymptomatic
Asymptomatic
Asymptomatic
CD4 Cell Count
Any value
CD4 <200 cells/mm3
CD4 >200 cells/mm3,
but <350 cells/mm3
CD4 >350 cells/mm3
CD4 >350 cells/mm3
Plasma HIV RNA
Any value
Any value
Any value
>100,000
copies/mm3
<100,000
copies/mm3
Recommendation
Treat
Treat
Treatment should
be offered following
full discussion of
the advantages
and disadvantages
of treatment
Most clinicians rec-
ommend deferring
therapy, but some
clinicians will treat
Defer therapy
*severe symptoms include unexplained fever or diarrhea for >two-four weeks, oral candidiasis, or
>10% unexplained weight loss.
3based regimens.  
The panel defines a "preferred" regimen as
one where clinical trial data have demon-
strated efficacy and durability with accept-
able tolerability and ease of use.  An "alter-
native" regimen is defined by the Panel as
a regimen that is efficacious, but has disad-
vantages compared to preferred regimens
in terms of antiviral activity, durability, toler-
ability, or ease of use.
Efavirenz (Sustiva) and lopinavir/ritonavir
fixed dose combination (Kaletra) remain
the preferred NNRTI and PI for initial thera-
py. With regard to the NRTI backbone,
stavudine has been moved from the pre-
ferred to the alternative list due to increas-
ing evidence of adverse events. Tenofovir
(Viread) and lamivudine (3TC) (or emtric-
itabine [FTC]) is recommended as a pre-
ferred and alternative NRTI backbone for
both NNRTI- and PI-based regimens. This
is the first time that emtricitabine has
appeared as either a preferred or alterna-
tive agent in the guidelines.
MANAGEMENT OF THE TREATMENT-
EXPERIENCED PATIENT
A full discussion of the management of
treatment-experienced patients is beyond
the scope of this article. However, the
Panel recommends that resistance testing
and expert advice should be part of this
management.  For more information, see
the December 2004 issue of IDCR, article
by Dr. Ian Frank "Use of HIV Resistance
Testing in Antiretroviral Therapy Decision
Making" (www.idcronline.org).  A summary
of the Panel's recommendations for experi-
enced patients follows:
w Although most patients experience bene-
fits from taking antiretroviral regimens,
adherence, intolerance/toxicity and phar-
macokinetic issues may complicate therapy
and virologic failure or treatment-limiting
toxicity occur commonly.
w Evaluation of ART failure should include
assessing the severity of HIV disease of the
patient; the antiretroviral treatment history,
including the duration, drugs used, anti-
retroviral potency, adherence history, and
drug intolerance/toxicity; and the results of
current and prior drug resistance testing.
w Virologic failure on treatment can be
defined as a confirmed HIV RNA level >400
copies/mm3 after 24 weeks, >50
copies/mm3 after 48 weeks, or repeated
HIV RNA level >400 copies/mm3 after prior
suppression of viremia to <400 copies/mm3.
w In managing virologic failure, the provider
should make a distinction between limited,
intermediate, and extensive prior treatment
exposure and resistance.
w The goal of treatment in those with limit-
ed or intermediate prior drug exposure and
whose viral isolates demonstrate limited or
intermediate drug resistance is to re-estab-
lish maximal virologic suppression.
w The goal of treatment in those with exten-
sive prior drug exposure and whose viral
isolates demonstrate extensive drug resis-
tance where viral suppression is difficult or
impossible to achieve with currently avail-
able drugs is preservation of immune func-
tion and prevention of clinical progression.
w Assessing and managing a patient with
extensive prior antiretroviral experience
and drug resistance who is experiencing
treatment failure is complex and expert
advice is critical.
TREATMENT INTERRUPTION AND
REINSTITUTION BASED ON CD4 CELL
COUNT (CD4 Guided Therapy)
The new guidelines briefly discuss the
option of discontinuing successful ART in
patients whose treatment was started when
the CD4 cell count was >350 cells/mm3 and
who might not meet recommendations for
initiating ART by today's guidelines.
Although no large, long term studies have
examined this strategy, several small stud-
ies and case reports seem to indicate that
there is little risk of resistance following a
single episode of treatment interruption.
When this strategy is employed, a target
CD4 count at which to resume therapy
should be discussed with the patient ahead
of time. The patient needs to know that
there will be an increase in VL that may be
associated with an increased risk of trans-
mission to sexual and needle-sharing part-
ners. 
SPECIAL POPULATIONS SECTION
This newly added section presents discus-
sion on considerations for ART in HIV-
infected adolescents, injection drug users,
HBV and HCV co-infected patients and HIV
infected patients with tuberculosis.
Although these sections address some of
the special issues faced in correctional HIV
care, other issues faced in corrections such
as method of pill distribution, educational
eeds of the correctional population, and
continuity of care upon discharge are not
addressed.
SUMMARY
The new guidelines that were released in
October 2004 push back the criteria for ini-
tiation of treatment and describe new rec-
ANTIRETROVIRAL THERAPY UPDATE...
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Table 3.  Preferred and Alternative Regimens
Preferred
Regimens
NNRTI-based
PI-based
Alternative
Regimens
NNRTI-based
PI-based
3 NRTI-based
REGIMENS
w Efavirenz* + (lamivudine or emtricitabine) + (zidovudine
or tenofovir)
w Lopinavir/ritonavir (Kaletra) + (lamivudine or emtric-
itabine) + zidovudine
w Efavirenz + (lamivudine or emtricitabine) + (abacavir or
didanosine or stavudine)
w Nevirapine + (lamivudine or emtricitabine) + (zidovudine
or stavudine or didanosine or abacavir or tenofovir)
w Atazanavir + (lamivudine or emtricitabine) + (zidovudine
or stavudine or abacavir or didanosine) or (tenofovir +
ritonavir 100 mg) 
w Fosamprenavir + (lamivudine or emtricitabine) + (zidovu-
dine or stavudine or abacavir or tenofovir or didanosine)
w Fosamprenavir/ritonavir + (lamivudine or emtricitabine) +
(zidovudine or stavudine or abacavir or tenofovir or didano-
sine)
w Indinavir/ritonavir + (lamivudine or emtricitabine) +
(zidovudine or stavudine or abacavir or tenofovir or didano-
sine)
w Lopinavir/ritonavir + (lamivudine or emtricitabine) +
(stavudine or abacavir or tenofovir or didanosine
w Nelfinavir + (lamivudine or emtricitabine) + (zidovudine
or stavudine or abacavir or tenofovir or didanosine)
w Saquinavir/ritonavir + (lamivudine or emtricitabine) +
(zidovudine or stavudine or abacavir or tenofovir or didano-
sine)
w Abacavir + Zidovudine + lamivudine - only when a pre-
ferred or an alternative NNRTI- or PI-based regimen can-
not or should not be used
# of pills
2-3
8-9
2-4
3-6
3-6
5-8
5-8
7-12
7-10
5-8
13-16
2
*efavirenz is not recommended for use in 1st trimester of pregnancy or in women with high preg-
nancy potential (women who want to conceive or who are not using birth control).
Summary continued on page 4
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ommendations for the initiation of treatment. It is important for the
correctional provider to understand that the guidelines are a "living
document" and can be expected to be modified on a yearly basis or
more frequently as further research is conducted. Important changes
to the guidelines will be noted in IDCR, and are also available at the
DHHS website (www.hhs.gov). The document provides a wealth of
information and should be required reading for all correctional HIV
providers. If perusing the greater than 100 page documents seems
overwhelming, one might opt for a more thorough reading of the
black boxes in the text of the document that summarize the recom-
mendations of the Panel and a review of the tables (these start on
page 41). And finally, these guidelines provide a framework for treat-
ment, which must involve a partnership with the patient. Most cor-
rectional HIV patients present with co-morbidities that complicate
treatment - these will be addressed in future issues of IDCR.
DISCLOSURES: *Consultant: Ortho Biotech, Grant/Research; 
Support: GlaxoSmithKline, Agouron, Merck, DCHD, Serono, Gilead, 
Chiron Corp, Boehringer-Ingelheim, Abbott Labs, Bristol-Myers Squibb; 
Speaker's Bureau: Roche, Bristol-Myers Squibb, Ortho Biotech
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HIV 101: Psychiatric and HIV Medication Interactions
Category
SSRIs
TCAs
Other: Wellbutrin
Other: Serzone
SNRIs
Other: Desyrel
Benzodiazepines
Non-
Benzodiazepine
sedative/hypnotics
Lithium carbonate
Anticonvulsants
First Generation -
Typical
Second Generation
- Atypical
Third Generation
St. John's Wort
NNRTIs
Prozac increases levels
of Rescriptor 50%
NPD
Sustiva may increase
wellbutrin levels.
NPD
NPD
NPD
NPD
NPD
NPD
Tegretol and Dilantin
may decrease levels of
PIs and NNRTIs.
NPD
NPD
NPD
May reduce blood levels
of NNRTIs.Induces
metabolism of Viramune;
increased clearance
~35%.
NRTIs
NPD*
NPD
NPD
NPD
NPD
NPD
NPD
NPD
NPD
Long term 
clinical 
implications not
known; monitor
for Retrovir 
toxicity.
NPD
NPD
NPD
NPD
PIs
Prozac may lead to increased effects of Norvir, but no dose
adjustment of Norvir is needed when used in combination.Norvir
increases levels of Prozac, Luvox, Paxil, and Zoloft.
Norvir decreases Norpramin clearance by 50%, causing higher
than anticipated blood levels; may increase levels of Elavil,
Sinequan, Tofranil, Depakote.When used in combination with
Norvir, caution is required.It is recommended to use lower
doses, and regularly monitor EKG and serum TCA levels.
Viracept and Norvir may increase wellbutrin levels, increasing
risk of drug-induced seizures.
Caution advised; combination of PIs and Serzone may increase
levels of both drugs.
Effexor may decrease Crixivan levels.
Potential for drug interactions when Desyrel is co-administered.
Adverse effects including nausea, hypotension, and syncope
were observed when Norvir and Desyrel were co-administered.It
is likely that Nizoral, Crixivan, and other CYP34A inhibitors may
lead to increases in Desyrel plasma concentrations with poten-
tial for adverse effects.  If Desyrel is used with a potent CYP34A
inhibitor, a lower dose of Desyrel should be considered.
Kaletra and Halcion may have possible interactions; Halcion and
other antipsychotics from this class are contraindicated in com-
bination with PIs due to the potential for serious and life-threat-
ening reactions such as prolonged or severe sedation or respi-
ratory depression.Xanax, Dalmane, Klonopin, and Valium should
be used in caution with PIs due to the potential for serious reac-
tions such as prolonged or severe sedation or respiratory
depression.Ativan, Restoril, and Tranxene are free of the seri-
ous interactions with PIs found with other benzodiazepines.
Ambien and Sonata should be used with caution in combination
with PIs due to the potential for serious reactions such as pro-
longed or severe sedation or respiratory depression.
NPD
Tegretol may decrease levels of PIs and NNRTIs.  Known to
decrease Crixivan levels with loss of viral suppression.  Tegretol
levels increased by Norvir.Dilantin: co-administered with Kaletra
results in decreased concentrations of both Dilantin and Kaletra.
Orap is contraindicated in combination with PIs due to potential
for serious and life-threatening reactions, such as cardiac
arrhythmia.Norvir may increase levels of antipsychotics.
PIs may increase plasma levels of Clozaril and increase the risk
for seizures and orthostatic hypotension.Geodon: caution is indi-
cated when Geodon is co-adminstered with Norvir.
NPD
May reduce blood levels of PIs.
*No Published Data about drug interactions specific to this combination.
These tables have been adapted from "Psychiatric Medications and
HIV Antiretrovirals: A Guide to Interactions for Clinicians."  
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In the early days of the AIDS epidemic, much of the basic pathogenesis and epidemiology of
HIV had not yet been clarified. Not enough was known about how the virus was transmitted, how
it could be prevented, how it caused immune deterioration, what infections and cancers infect-
ed persons were at risk for, and how these opportunistic infections could be prevented. As a
result, the management of those with HIV infection was relegated to infectious disease special-
ists and to a small cadre of dedicated pioneers drawn from a variety of medical fields. 
By the end of the 1980s, much of the basic details concerning HIV had been elucidated. Soon,
the number of cases of HIV in this country overwhelmed the available specialists. Because of
the simplicity of the limited treatment options (essentially PCP prophylaxis and AZT) most pri-
mary care clinicians were able to manage the treatment of those infected with HIV.
The 1990s witnessed a dramatic increase in treatment options for HIV and related illnesses.
Along with these new treatments have come severe, potentially fatal side effects and a myriad
of complex pharmacokinetic interactions. Outcome based studies have demonstrated that
patients who do not receive care from clinicians who specialize in the management of HIV are
at a greater risk for HIV related morbidity. Furthermore, the life expectancy of those who are
HIV-infected is directly related to the experience of their physician. Clearly, we have come full
circle, in that only those clinicians who make it a priority are able to master the complexities of
the care of the HIV-infected.  We can all hope that in the future the HIV specialist will be obso-
lete… until that time, we have a responsibility to ensure that those inmates entrusted to our care
have access to clinicians who specialize in the management of HIV. 
This month, Dr. David Paar provides an update on guidelines for the treatment of HIV. Dr.
Bethany Weaver presents a case that discusses some of the challenges of using efavirenz in
those who have a major mental illness, and our HIV 101 details some of the pharmacokinetic
interactions that can occur between antiretroviral agents and psychotropics.  At the conclusion
of this issue, readers will be more familiar with the new HIV treatment guidelines, be aware of
potential for drug interactions between HAART and psychotropics, and know more about the
potential side effects of efavirenz. 
Beginning next month, Dr. David Thomas will assume the role of co-chief editor managing con-
tent for IDCR.  We welcome Dr. Thomas to this new role, and we also welcome three new mem-
bers to our editorial board: Dr. William Cassidy, Associate Professor of Medicine at Louisiana
State University Health Sciences Center, Dr. Neil Fisher, Medical Director and Chief Health
Officer of Martin Correctional Institute; and Barry Zack, MPH, Executive Director of Centerforce.
Thank you for your continued readership of IDCR, and we encourage your suggestions con-
cerning future topics.
Sincerely,
Joseph Bick, MD
LETTER FROM THE EDITOR
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6ASK THE EXPERT: Case Study - Acute Psychosis in a Patient with AIDS
By Bethany Weaver*, D.O., M.P.H., Acting Instructor of Medicine, University of Washington Center for AIDS & STD Research (CFAR) and Northwest
Correctional Medicine Education Program. DISCLOSURES: *Pfizer: Stockholder
Q: What potential adverse effects should you warn him
about?
A: He should be warned about the potential for hallucinations,
precipitation of mania, insomnia, depression, and nightmares on
efavirenz, particularly in the first 10-14 days on the drug.  You tell
him that you are hesitant about placing him on the drug because
of the potential for these symptoms, particularly with his history of
bipolar disorder. However, you realize he has limited protease
inhibitor treatment options. You rationalize that if he is going to
develop adverse effects on efavirenz, at least they will occur in a
supervised, safe setting while he is incarcerated. You also rec-
ommend that he see psychiatry more regularly (e.g. every two
weeks) for the first few months on this regimen. 
He returns for follow-up two weeks later and appears anxious with
pressured speech.  He reports some mild insomnia but is feeling
"better than I've felt in years".  Also, he loves taking the efavirenz
because it is only one pill at bedtime, which he feels improves his
adherence.  
Q:  Do you have any concerns at this time? What other ques-
tions should you ask him? When should you see him again
in clinic?
A: Yes, you should be concerned about precipitation of mania
with potential for it to progress over the next few weeks. You
should ask him when he is taking efavirenz since it was pre-
scribed as “keep on person”, making it difficult to be sure what
time he is taking it every day.  If he is taking the drug within an
hour or so of a high fat meal, the absorption will be increased with
higher risk for side effects.  Since efavirenz is cleared in the liver
via the cytochrome P450 system, a review of his other medica-
tions is warranted to be sure there are no significant drug-drug
interactions, and checking a lithium level, liver function tests and
evaluating for hepatitis B and C and undetected cirrhosis would
be reasonable. Finally, you recommend he see you again in two
weeks so you can re-evaluate his tolerability of the new regimen. 
Q: Are there any other tests to consider at this time?
A: A plasma efavirenz level (trough) can be performed with a
blood draw and is probably best drawn eight-15 hours after the
dose is taken, which is typically in the morning since most patients
take the drug in the evening to minimize side effects. This test is
performed at reference laboratories and may take two-four weeks
for a result to be received. If the level is above 4000mg/l, CNS tox-
icity may be three times more likely than if the level is below this
cutoff.  Virologic failure is more often seen when the level is below
1000mg/l. It is speculated that a level somewhere between 1000
and 4000mg/l is best for optimal efficacy and tolerability.
Unfortunately, because of the long return time for the efavirenz
level, it is difficult to use the results of this test as a clinical tool in
the management of the patient and is not likely cost-effective for
this reason.  Decisions in response to a drug level above 4000
m/gml may be difficult as there are no published guidelines for
dose reduction needed with an elevated efavirenz level.  
The inmate returns to see you two weeks later. Over the last two
weeks, he has received three infractions due to violent outbursts,
is paranoid and delusional, and was sent to segregation, then the
mental health unit due to concern for his safety and the safety of
others.  He is still reluctant to stop the new regimen since he “feels
great” and his CD4 count is now 160 cells/ml (15%) with HIV-1
viral load of 5,000 copies/ml after three weeks on the drugs.  His
lithium level and LFTs were normal, and he had no evidence of
chronic active hepatitis B or C.  
Discussion
Though efavirenz is an attractive HIV treatment option because of
its long half-life (only dosed once a day) and high tolerability after
the first two weeks, it presents some challenges for use in the
incarcerated setting. First, the meals in the correctional setting are
typically high in fat and difficult to control, and this may contribute
to risk of CNS toxicity. If the drug is taken two-three or more hours
after dinner, this problem should be minimized. However, the bed-
time pill line in corrections is often shortly after dinner, rather than
at 9 or 10 p.m. If the inmate keeps the drug on person, the inmate
c ld then take the dose at 10 p.m. with only a light snack or on
an empty stomach. Second, though the risk for severe neurotoxi-
city in the general population appears low (only discontinued in
approximately 4% of patients due to severity or persistence of
adverse effects), it is likely higher among incarcerated individuals
since they often have a history of significant prior mental illness as
well as underlying significant liver disease from hepatitis C and/or
alcohol. Third, when psychosis does occur in the incarcerated set-
ting, it can be quite detrimental to the inmate. The patient in this
case received numerous infractions for his behavior with an
extended sentence, was placed on the mental health unit for
observation, and required intensive psychiatric monitoring. The
drug was discontinued as his mania and psychosis were not man-
ageable despite intensive psychiatric care and addition of antipsy-
chotics, and the effects lasted for several weeks, even after dis-
continuing the medication.  
In patients who require salvage therapy and have risk factors for
CNS toxicity, it is reasonable to consider use of efavirenz in a
supervised setting, such as the correctional setting. The potential
for problems should be weighed against potential benefits, partic-
ularly in patients who have advanced HIV/AIDS. It is important to
counsel the patient and the staff about the potential complica-
tions. The role of therapeutic drug monitoring is still unclear.
Optimal use requires dose adjustment on the basis of a drug
level.  More research on this topic is needed in order for this prac-
tice to be cost-effective and clinically meaningful for the patient.
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CASE: A 33 year-old male inmate presents with untreated C3 HIV/AIDS in need of treatment. His CD4 cell count and HIV-1 viral load
two months ago were 100 cells (13%) and 100,000 copies/ml, respectively. He is taking trimethoprim/sulfamethoxazole and
azithromycin for PCP and MAC prophylaxis and has been off antiretroviral medications for six months due to intolerance and virologic
failure, known because he had genotype resistance assays in his record documenting high level resistance to all available protease
inhibitors. He has never taken efavirenz (sustiva) or nevirapine (viramune). He is an injecting drug user with a history of bipolar disor-
der for which he receives lithium by directly observed therapy (DOT). He has no history of suicide attempts and has been hospitalized
twice with mania after cocaine use.  He weighs 145 pounds and has an unremarkable physical exam. He has two years remaining in
his sentence.  He tells you that he would like to resume antiretroviral medications as soon as possible due to increasing fatigue and
worsening memory but is concerned about his ability to remain adherent if the regimen is too complicated. You recommend he start
tenofovir, lamivudine, and efavirenz.
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Hepatitis A Vaccine Safe in HIV Patients
Hepatitis A virus (HAV) is common among persons
who are at highest risk for HIV infection. One hun-
dred eighty subjects, 90 of whom were HIV-infect-
ed were given an inactivated HAV vaccine to deter-
mine the safety and efficacy in HIV-infected
patients. The HIV-infected subjects were stratified
into two groups: one group with CD4 cell counts
<300cells/mm3 and one group with CD4 cell counts
>300cells/mm3.  Vaccine or placebo was adminis-
tered at zero and 24 weeks. At week 28, serocon-
version rates among HIV-infected and HIV-unin
fected subjects were 94% and 100%, respectively.
Additionally, HIV-infected subjects with CD4 cell
counts <300 cells/mm3 had a seroconversion rate
of 87%, while HIV-infected subjects with CD4 cell
counts >300 cells/mm3 had a seroconversion rate
of 100%. Conclusions drawn from this study are
that HAV vaccine is immunogenic and safe among
HIV-infected persons, and should be part of their
preventative care.
Clin Infect Dis 2004; 39:1207-13.
Combination Therapy for HBV
Thirty treatment naïve, hepatitis B virus (HBV) e
antigen positive (HBeAg+) patients were random-
ized to receive adefovir dipivoxil (ADV) plus emtric-
itabine (FTC) or ADV plus placebo for 48 weeks.
The study aims were to compare the efficacy of a
new combination therapy of ADV plus FTC versus
ADV monotherapy.  At baseline, median HBV DNA
was 7.6 log copies/ml in the ADV plus FTC arm
and 8.5 log copies/ml in the ADV arm. The median
log change from baseline HBV DNA was -3.95 for
the ADV plus FTC arm and -2.44 for the ADV arm.
HBeAg seroconversion occurred in three patients
total; two in the combination arm and one in the
ADV arm. Additionally, 80% of HbeAg positive
patients taking ADV plus FTC had undetectable
HBV DNA, versus 20% taking ADV alone at 48
weeks.  Combination therapy with ADV plus FTC
may be superior to ADV alone, at least in the short
term.
www.natap.org
Risk of Early Virologic Failure with
ddI+TDF+NNRTI
Two studies reported at the 2004 ICAAC meeting
found that regimens combining the
nucleoside/nucleotide analogs didanosine (ddI)
and tenofovir disoproxil fumarate (TDF), plus either
efavirenz (EFV) or nevirapine (NVP) can cause
early virologic failure in treatment-naïve persons,
particularly in those persons commencing treat-
ment with a high viral load. Podzamczer et. al.
found that 43% of people taking TDF/ddI/efavirenz
had virologic failure, defined as less than a two log
drop in viral load by month three of their study.
None of the subjects taking TDF/ddI/efavirenz plus
lopinavir/ritonavir had virologic failure.  In a larger
study conducted by Moyle et al, 44 subjects were
randomized to start TDF/ddI/efavirenz and 36 were
randomized to start 3TC/ddI/efavirenz. While
adherence exceeded 99% in both groups, virolog-
ic failure in the TDF/ddI/efavirenz group and
3TC/ddI/efavirenz group were 12% and 0%,
respectively.  All people with a virologic failure had
a pretreatment CD4 count below 200 cells/uL and
a viral load greater than 100,000 copies/mL. The
mechanism of early virologic failure in these
patients is unclear. Clinicians should use caution
when coadministering ddI/TDF and either EFV or
NVP in treatment-naïve patients with high baseline
viral loads.  
www.natap.org
Tenofovir for the Treatment of Lamivudine-
Resistant Hepatitis B Virus (HBV)
Adefovir dipivoxil, which was recently approved for
the treatment of wild-type and lamivudine-resistant
HBV infection, and tenofovir disoproxil fumarate
(TDF) were compared in a study of 53 subjects to
measure the decline of HBV DNA levels in lamivu-
dine-resistant HBV infection. Thirty-five subjects
received TDF 300 mg/day for 72-130 weeks, while
18 subjects received adefovir 10mg/day for 60-80
weeks. The TDF-treated group was further divided
into three groups: HBV-infected subjects, HIV/HBV
coinfected subjects who had received TDF as a
part of antiretroviral therapy, and immunosup-
pressed HBV-infected subjects following kidney
transplantation. None of the adefovir subjects had
these comorbidity features.  Subjects were
matched for age, sex, ALT levels, hepatitis B e
antigen (HBeAg) status, and HBV DNA level at
baseline. All TDF-treated subjects showed a
strong and early suppression of HBV DNA within a
few weeks, including the HIV coinfected subjects.
At week 48, 100% of the TDF-treated subjects had
HBV DNA levels below 105 copies/mL, in contrast
t  only 44% of those subjects treated with adefovir.
While tenofovir has not been approved for the
treatment of HBV, this study shows that it may
become an effective alternative for the treatment of
patients with lamivudine-resistant HBV infection.
H patology; 2004: 40:6
Barriers to Care of HCV for Drug Users
Five hundred fifty-seven HIV-seropositive and HIV-
seronegative current and former injection drug
users were enrolled in a prospective study to
gauge the natural history of hepatitis C virus (HCV)
infection. The 228 subjects with chronic HCV infec-
tion were offered referral for HCV evaluation and
treatment; only 56% accepted referrals. Reasons
study participants gave for declining referrals
included self-reported clinical care elsewhere
(62%), not interested or too busy (16%), or not
r ady (9%).  Additional reasons included fear of
biopsy or treatment, unable to keep appointments,
and end-stage liver disease.  Of the 56% of sub-
jects who did accept referrals, only 43% arrived for
valuation, which was located two city blocks from
the research site.  Additionally, of those who did
arrive for evaluation, only 22% had a liver biopsy,
and only 7% were treated. Despite counseling
about HCV infection and the need for medical eval-
uation, only a small percentage of subjects actual-
ly followed through to treatment. This study sug-
g sts that there must be other barriers, besides
access to care, that inhibit HCV infected injection
drug users from seeking and receiving treatment. 
www.natap.org
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SELF-ASSESSMENT TEST FOR CONTINUING MEDICAL EDUCATION CREDIT
Brown Medical School designates this educational activity for one hour in category one credit toward the AMA Physician’s Recognition
Award. To be eligible for CME credit, answer the questions below by circling the letter next to the correct answer to each of the questions. 
A minimum of 70% of the questions must be answered correctly. This activity is eligible for CME credit through June 30, 2005. 
The estimated time for completion of this activity is one hour and there is no fee for participation.
1. Based upon the most recent guidelines for the treatment of
adults with HIV, the following individuals should be offered anti-
retroviral therapy:
a. All those with CD4 counts less than 500
b. All those with HIV viral loads greater than 55,000
c. All those who have an HIV related opportunistic infection
d. All those who are co-infected with hepatitis C
2. Which of the following statements is false:
a. Efavirenz and kaletra are preferred agents in the new HIV 
treatment guidelines
b. Didanosine, emtricitabine, lamivudine, and tenofovir can 
be dosed once daily
c. Stavudine has been linked to a lower risk for lipoatrophy
d. Ritonavir can cause an increase in triglycerides
3. The following protease inhibitors cannot be used in once daily
regimens:
a. Nelfinavir
b. Amprenavir
c. Atazanavir
d. Saquinivir
4. The following antiretroviral combinations should be avoided:
a. Tenofovir plus didanosine
b. Emtricitabine plus lamivudine
c. Azidothymidine plus stavudine
d. Didanosine plus stavudine
e. Efavirenz plus nevirapine
f.  All of the above
5. Which of the following statements is false:
a. When used in combination with ritonavir, the dose of 
amprenavir should be increased
b. When used in combination with efavirenz, the dose of 
kaletra should be increased
c. When used in antiretroviral experienced patients, 
atazanavir should be boosted with ritonavir
d. When used in patients who are receiving ritonavir, the 
dose of fuzeon need not be changed
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IDCR EVALUATION
5 Excellent    4 Very Good    3 Fair    2 Poor    1 Very Poor
1. Please evaluate the following sections with respect to:
educational value clarity
Main Article 5  4  3  2  1   5  4  3  2  1      
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2. Do you feel that IDCR helps you in your work?
Why or why not?
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